Rx Regulatory Puzzle: FDA’s 2015 Agenda Comes Together Piece By Piece
Executive Summary
Generic drug labeling, drug shortages and compounding will be tackled in regulations in 2015; three documents weave together a picture of FDA’s upcoming actions on pharmaceutical-related rules.
You may also be interested in...
FDA Adverse Event Reporting Reg Offers Few Exceptions
Companies must submit post-market safety reports electronically beginning in June 2015; waivers will be allowed, but they would only be temporary.
National Licensing Standard For Wholesale Distributors Gains Momentum
In the face of counterfeit drug problems and questions over the safety of the nation's drug supply, momentum appears to be building for a national wholesale distributor licensing standard
FDA’s Authority Looks Safe From Judicial Interference Following Supreme Court Abortion Pill Arguments
The agency's and the pharma industry’s worst fears – that a potential ruling in the mifepristone case might usurp the FDA’s scientific authority and throw the stability of the US drug approval process into question – seem unlikely to materialize as the majority of the Supreme Court justices signal the Alliance for Hippocratic Medicine lacks standing to sue.